Profit before tax (PBT) for the March quarter stood at Rs 47.19 crore, marking a robust 106.07% rise from Rs 22.90 crore reported in the same period last year.
Total expenses rose 6.92% YoY to Rs 143.93 crore during the quarter. Employee benefits expenses stood at Rs 33.47 crore (up 25.97%), while the cost of materials consumed was at Rs 48.71 crore (up 5.62% YoY) during the period under review.
The company's revenue from Diagnostic Testing Services was at Rs 172.69 crore (up 22.38% YoY), while revenue from Imaging Services stood at Rs 13.68 crore (up 7.21% YoY) in Q4 FY25.
EBITDA improved 70% YoY to Rs 57.4 crore in the March 2025 quarter from Rs 33.8 crore reported in the corresponding period the previous year. EBITDA margin increased to 31% in Q4 FY25 compared to 22% reported in the corresponding quarter last fiscal year.
Meanwhile, the Board has recommended a final dividend of Rs 21 per equity share for FY25, subject to shareholder approval.
Thyrocare Technologies is engaged in the healthcare industry and is involved in providing quality diagnostic services at affordable costs to patients, laboratories, and hospitals in India.